DONG-A ST CO.,LTD Logo

DONG-A ST CO.,LTD

Develops and distributes ethical drugs, medical devices, and diagnostics for global healthcare.

170900 | KO

Overview

Corporate Details

ISIN(s):
KR7170900005
LEI:
Country:
South Korea
Address:
서울 동대문구 용두동 138 ~255 천호대로 64, 서울
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dong-A ST Co., Ltd. is a specialized pharmaceutical and medical device company that spun off from Dong-A Socio Group in 2013. The company focuses on the development, manufacturing, and global distribution of ethical drugs (ETC), medical devices, and diagnostics. Its pharmaceutical portfolio includes domestically developed new drugs such as Stillen and Zydena, biopharmaceuticals, and chemical drugs. Dong-A ST is also a major global manufacturer of the tuberculosis API, Cycloserine. The medical device and diagnostics division provides comprehensive healthcare solutions in areas including ENT (Ear, Nose, Throat) equipment, in-vitro diagnostics, and infection control systems. With a strong emphasis on research and development, the company actively pursues international expansion through global partnerships and exports.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Prospectus
투자설명서
Korean 2.8 MB
2025-09-09 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 47.8 KB
2025-09-08 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 14.6 KB
2025-09-03 00:00
Registration Form
[기재정정]증권신고서(채무증권)
Korean 3.1 MB
2025-09-03 00:00
Prospectus
[발행조건확정]증권신고서(채무증권)
Korean 275.8 KB
2025-08-28 00:00
Registration Form
증권신고서(채무증권)
Korean 2.8 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.3 MB
2025-08-13 00:00
Earnings Release
[기재정정]영업(잠정)실적(공정공시)
Korean 18.0 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 239.2 KB
2025-07-24 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.8 KB
2025-07-24 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.6 KB
2025-07-18 00:00
Report Publication Announcement
결산실적공시예고(안내공시)
Korean 4.1 KB
2025-07-18 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.8 KB
2025-07-07 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 61.5 KB
2025-07-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB

Automate Your Workflow. Get a real-time feed of all DONG-A ST CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DONG-A ST CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DONG-A ST CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.